Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 4
2017 2
2018 6
2019 7
2020 13
2021 13
2022 10
2023 12
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigós L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernández-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortés J, Braga S. Pérez-García JM, et al. Among authors: cejalvo jm. Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144. Neuro Oncol. 2023. PMID: 35639825 Free PMC article. Clinical Trial.
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. Schettini F, et al. Among authors: cejalvo jm. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2. NPJ Breast Cancer. 2021. PMID: 33397968 Free PMC article.
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo JM. Adam-Artigues A, et al. Among authors: cejalvo jm. Sci Adv. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. Epub 2022 May 20. Sci Adv. 2022. PMID: 35594351 Free PMC article.
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galván P, Fan C, Selitsky SR, Coffey AR, Marron D, Brasó-Maristany F, Burgués O, Albanell J, Rojo F, Lluch A, de Dueñas EM, Rosen JM, Johnson GL, Carey LA, Prat A, Perou CM. Garcia-Recio S, et al. Among authors: cejalvo jm. J Clin Invest. 2020 Sep 1;130(9):4871-4887. doi: 10.1172/JCI130323. J Clin Invest. 2020. PMID: 32573490 Free PMC article.
In the literature: May 2023.
Gambardella V, Cejalvo JM, Cervantes A. Gambardella V, et al. Among authors: cejalvo jm. ESMO Open. 2023 Jun;8(3):101562. doi: 10.1016/j.esmoop.2023.101562. Epub 2023 May 15. ESMO Open. 2023. PMID: 37196398 Free PMC article. No abstract available.
AXL - a new player in resistance to HER2 blockade.
Adam-Artigues A, Arenas EJ, Arribas J, Prat A, Cejalvo JM. Adam-Artigues A, et al. Among authors: cejalvo jm. Cancer Treat Rev. 2023 Dec;121:102639. doi: 10.1016/j.ctrv.2023.102639. Epub 2023 Oct 7. Cancer Treat Rev. 2023. PMID: 37864955 Free article. Review.
In the literature: February 2022.
Gambardella V, Cejalvo JM, González-Barrallo I, Gimeno-Valiente F, Cervantes A. Gambardella V, et al. Among authors: cejalvo jm. ESMO Open. 2022 Apr;7(2):100411. doi: 10.1016/j.esmoop.2022.100411. Epub 2022 Feb 24. ESMO Open. 2022. PMID: 35219243 Free PMC article. No abstract available.
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Peña R, Montañés JC, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. Pérez-Núñez I, et al. Among authors: cejalvo jm. Nat Cancer. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. Epub 2022 Mar 17. Nat Cancer. 2022. PMID: 35301507
In the literature: November 2022.
Gambardella V, Cejalvo JM, Cervantes A. Gambardella V, et al. Among authors: cejalvo jm. ESMO Open. 2022 Dec;7(6):100643. doi: 10.1016/j.esmoop.2022.100643. Epub 2022 Nov 17. ESMO Open. 2022. PMID: 36403559 Free PMC article. No abstract available.
In the Literature: January 2023.
Martín-Arana J, Gambardella V, Tarazona N, Cejalvo JM, Cervantes A. Martín-Arana J, et al. Among authors: cejalvo jm. ESMO Open. 2023 Feb;8(1):100763. doi: 10.1016/j.esmoop.2022.100763. Epub 2023 Jan 3. ESMO Open. 2023. PMID: 36603523 Free PMC article. No abstract available.
71 results